Phase II study of LU 103793 (dolastatin analogue) in patients with metastatic breast cancer

被引:46
作者
Kerbrat, P [1 ]
Dieras, V
Pavlidis, N
Ravaud, A
Wanders, J
Fumoleau, P
机构
[1] Ctr Eugene Marquis, Rennes, France
[2] Inst Curie, Paris, France
[3] Univ Ioannina, Sch Med, GR-45110 Ioannina, Greece
[4] Inst Bergonie, Bordeaux, France
[5] NDDO Oncol, Amsterdam, Netherlands
[6] Ctr Rene Gauducheau, F-44035 Nantes, France
关键词
phase II; breast cancer; LU; 103793; dolastatin;
D O I
10.1016/S0959-8049(02)00531-2
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
LU 103793 is a synthetic analogue of Dolastatin 15 that inhibits tubulin polymerisation. The aim of this study was to evaluate the efficacy and tolerability of LU 103793 in patients with metastatic breast cancer who had been previously treated with two lines of chemotherapy for advanced disease. Patients received LU 103793 at a dose of 2.5 mg/m(2)/day over 5 min for 5 consecutive days every 3 weeks. Thirty-four patients were enrolled and 23 patients were eligible for the evaluation of efficacy. Eleven patients experienced grade 4 neutropenia. Other related grade 3/4 adverse events included asthenia (three patients), stomatitis (1), myalgia (1) and increase of serum bilirubin (2). The main toxicity was hypertension occurring in seven out of 34 patients. There were no objective responses, 7 patients had stable disease. These results do not support the further evaluation of LU 103793 in metastatic breast cancer patients using this dose and schedule. (C) 2003 Elsevier Science Ltd. All rights reserved.
引用
收藏
页码:317 / 320
页数:4
相关论文
共 50 条
  • [41] Phase II study evaluating the efficacy and safety of sagopilone (ZK-EPO) in patients with metastatic breast cancer that has progressed following chemotherapy
    Phuong K. Morrow
    Stephen Divers
    Louise Provencher
    Shiuh-Wen Luoh
    Teresa M. Petrella
    Marius Giurescu
    Thomas Schmelter
    Yao Wang
    Gabriel N. Hortobagyi
    Linda T. Vahdat
    Breast Cancer Research and Treatment, 2010, 123 : 837 - 842
  • [42] Phase II study evaluating the efficacy and safety of sagopilone (ZK-EPO) in patients with metastatic breast cancer that has progressed following chemotherapy
    Morrow, Phuong K.
    Divers, Stephen
    Provencher, Louise
    Luoh, Shiuh-Wen
    Petrella, Teresa M.
    Giurescu, Marius
    Schmelter, Thomas
    Wang, Yao
    Hortobagyi, Gabriel N.
    Vahdat, Linda T.
    BREAST CANCER RESEARCH AND TREATMENT, 2010, 123 (03) : 837 - 842
  • [43] Multicenter phase II trial of weekly paclitaxel for advanced or metastatic breast cancer: the Saitama Breast Cancer Clinical Study Group (SBCCSG-01)
    Sato, K
    Inoue, K
    Saito, T
    Kai, T
    Mihara, H
    Okubo, K
    Koh, J
    Mochizuki, H
    Tabei, T
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2003, 33 (08) : 371 - 376
  • [44] Phase II Study of an Outpatient Palliative Care Intervention in Patients With Metastatic Cancer
    Follwell, Matthew
    Burman, Debika
    Le, Lisa W.
    Wakimoto, Kristina
    Seccareccia, Dori
    Bryson, John
    Rodin, Gary
    Zimmermann, Camilla
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (02) : 206 - 213
  • [45] Phase I/II study of biweekly vinorelbine and oxaliplatin as first-line treatment in patients with metastatic breast cancer
    Guerrero, Antonio
    Servitja, Sonia
    Rodriguez-Lescure, Alvaro
    Calvo, Lourdes
    del Barco, Sonia
    Teresa Quintanar, Maria
    Ignacio Juarez, Jose
    Gayo, Javier
    Llombart, Antonio
    Tusquets, Ignasi
    ANTI-CANCER DRUGS, 2011, 22 (03) : 283 - 289
  • [46] A phase II study of oral enzastaurin in patients with metastatic breast cancer previously treated with an anthracycline and a taxane containing regimen
    Lida Mina
    Ian Krop
    Robin T. Zon
    Steven J. Isakoff
    Charles J. Schneider
    Menggang Yu
    Cindy Johnson
    LaTrice G. Vaughn
    Yanping Wang
    Maria Hristova-Kazmierski
    Oluwatoyin O. Shonukan
    George W. Sledge
    Kathy D. Miller
    Investigational New Drugs, 2009, 27 : 565 - 570
  • [47] Vinorelbine, cisplatin and continuous infusion of 5-fluorouracil (ViFuP) in metastatic breast cancer patients:: A phase II study
    Nolè, F
    Munzone, E
    Mandalà, M
    Catania, C
    Orlando, L
    Zampino, MG
    Minchella, I
    Colleoni, M
    Peruzzotti, G
    Marrocco, E
    Goldhirsch, A
    ANNALS OF ONCOLOGY, 2001, 12 (01) : 95 - 100
  • [48] A phase II study of oral enzastaurin in patients with metastatic breast cancer previously treated with an anthracycline and a taxane containing regimen
    Mina, Lida
    Krop, Ian
    Zon, Robin T.
    Isakoff, Steven J.
    Schneider, Charles J.
    Yu, Menggang
    Johnson, Cindy
    Vaughn, LaTrice G.
    Wang, Yanping
    Hristova-Kazmierski, Maria
    Shonukan, Oluwatoyin O.
    Sledge, George W.
    Miller, Kathy D.
    INVESTIGATIONAL NEW DRUGS, 2009, 27 (06) : 565 - 570
  • [49] Phase II study of pemetrexed in breast cancer patients pretreated with anthracyclines
    Martin, M
    Spielmann, M
    Namer, M
    duBois, A
    Unger, C
    Dodwell, D
    Vodvarka, P
    Lind, M
    Calvert, H
    Casado, A
    Zelek, L
    Lluch, A
    Carrasco, E
    Kayitalire, L
    Zielinski, C
    ANNALS OF ONCOLOGY, 2003, 14 (08) : 1246 - 1252
  • [50] Phase II trial of dexverapamil and epirubicin in patients with non-responsive metastatic breast cancer
    Lehnert, M
    Mross, K
    Schueller, J
    Thuerlimann, B
    Kroeger, N
    Kupper, H
    BRITISH JOURNAL OF CANCER, 1998, 77 (07) : 1155 - 1163